⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IVVD News
Invivyd, Inc. Common Stock
Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
globenewswire.com
IVVD
Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
globenewswire.com
IVVD
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
IVVD
Form 8-K
sec.gov
IVVD
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
globenewswire.com
IVVD
Invivyd to Participate in Upcoming September Investor Conferences
globenewswire.com
IVVD
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
IVVD
Form 8-K
sec.gov
IVVD
Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
globenewswire.com
IVVD
Form 8-K
sec.gov
IVVD